RBC Capital Maintains Outperform on ADC Therapeutics, Lowers Price Target to $9
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza maintains ADC Therapeutics (NYSE:ADCT) with an Outperform rating but lowers the price target from $10 to $9.
August 09, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on ADC Therapeutics but lowers the price target from $10 to $9.
The news is directly related to ADC Therapeutics. While the Outperform rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's performance in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100